“Clinical trial limitations exist in every trial. The results of the clinical trials might not be applied to every individual and the study duration might not be long enough to conclude the long-term safety and tolerability of the new medication.”

Chia-Chun Chiang, MD, recently conducted a study that was presented at the 2020 American Headache Society (AHS) Annual Meeting that not only evaluated the real-world efficacy, tolerability, and safety of ubrogepant (Ubrelvy; Allergan), rimegepant (Nurtec ODT; Biohaven), and lasmiditan (Reyvow; Eli Lilly), but headlined an overall trend of studies that evaluated previously FDA approved drugs. This time, the results of the trial were reported in a largely chronic migraine (81%) patient population.

The migraine community especially has seen drastic increase in number of options and treatments available for a multitude of differing migraine populations worldwide over the past decade. Chiang, a neurologist at Mayo Clinic in Phoenix, Arizona, noted that these types of studies are important for improving clinical care and reaching different subgroups of patients.

In an interview with NeurologyLive, Chiang describes the clinical importance of conducting real-world studies following drug approvals, as well as the future impact these data can have on clinical and patient care in migraine going forward.